Drug
Nivolumab And Intensity Modulated Radiotherapy
Nivolumab And Intensity Modulated Radiotherapy: highest development phase Phase 2, developed by Bristol-Myers Squibb. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Bristol-Myers Squibb
Trials
| Drug | Phase | Indication |
|---|---|---|
| Nivolumab and Intensity Modulated Radiotherapy (IMRT) NCT04577638 | Phase 2 | Non Small Cell Lung Cancer Stage III |
Latest
No recent events.
Follow Nivolumab And Intensity Modulated Radiotherapy on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.